Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients


A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection




With new strategies and drugs available, many different regimens exist for the treatment of HIV. The purpose of this study is to compare three different anti-HIV drug regimens as first-time treatments for HIV infection.

Study Status: Completed


Condition Intervention Phase
HIV Infections Drug: Lopinavir/ritonavir
Drug: Efavirenz
Drug: Stavudine
Drug: Zidovudine
Drug: Lamivudine
Drug: Tenofovir disoproxil fumarate
Phase 3

Verified by National Institute of Allergy and Infectious Diseases (NIAID) May, 2012

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID) identifier: NCT00050895

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation, Div. of Medicine, Infectious Diseases
Cleveland, Ohio 44109-5083
United States

Sharon Riddler, MD., Study Chair
Richard Haubrich, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site